Key facts
- It has raised $12.0M across 1 recorded rounds; the latest was Early Stage VC ($13.8M) in Nov 2025.
- Notable investors include Biogen.
- Neela Therapeutics has filed 1 Form D with the SEC, most recently Nov 2025 ($12.0M sold to 17 investors).
- Status: Privately Held (backing).
Investors
1Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Neela Therapeutics
Create free account
No card required
Funding rounds
1 roundsAbout Neela Therapeutics
Developer of a pediatric central nervous system therapy designed to address rare neuro-genetic diseases. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- Lunenburg, MA, United States
- Founded
- 2025
- Employees
- 5
- Website
- neelatx.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Neela Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Neela Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Neela Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.